MS brains had fewer signs of Alzheimer's disease

Credibility

Interest

Share:1 min read

Key Takeaway

Donated brain tissue from people with MS had less of two changes linked to Alzheimer's disease than tissue from people without MS.

What They Found

Researchers examined brain tissue donated after death. They looked at two kinds of buildup linked to Alzheimer's disease: plaques and tangles. Tissue from people with MS had fewer plaques than tissue from people without MS, especially among those under 65. It also had fewer tangles, particularly among those over 65. In both groups, more plaques were linked to more tangles.

Who Should Care and Why

This study examined donated brain tissue from people with and without MS. It focused on areas near the front and sides of the brain. The findings describe differences in changes linked to Alzheimer's disease, not differences in memory or daily function. The plaque difference was most noticeable in people under 65. The tangle difference was most noticeable in people over 65.

Important Considerations

You should know that researchers examined tissue from 75 people with MS and 66 people without MS after death. This study did not follow people over time or test a treatment. It cannot show why the brain tissue differed between the groups.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News